Top

European Archives of Psychiatry and Clinical Neuroscience

Published in:

Open Access 01-06-2020 | Schizophrenia | Original Paper

Phosphodiesterase 10A levels are related to striatal function in schizophrenia: a combined positron emission tomography and functional magnetic resonance imaging study

Authors: Jonas Persson, K. Szalisznyó, G. Antoni, A. Wall, D. Fällmar, H. Zora, R. Bodén

Published in: European Archives of Psychiatry and Clinical Neuroscience | Issue 4/2020

Abstract

Pharmacological inhibition of phosphodiesterase 10A (PDE10A) is being investigated as a treatment option in schizophrenia. PDE10A acts postsynaptically on striatal dopamine signaling by regulating neuronal excitability through its inhibition of cyclic adenosine monophosphate (cAMP), and we recently found it to be reduced in schizophrenia compared to controls. Here, this finding of reduced PDE10A in schizophrenia was followed up in the same sample to investigate the effect of reduced striatal PDE10A on the neural and behavioral function of striatal and downstream basal ganglia regions. A positron emission tomography (PET) scan with the PDE10A ligand [¹¹C]Lu AE92686 was performed, followed by a 6 min resting-state magnetic resonance imaging (MRI) scan in ten patients with schizophrenia. To assess the relationship between striatal function and neurophysiological and behavioral functioning, salience processing was assessed using a mismatch negativity paradigm, an auditory event-related electroencephalographic measure, episodic memory was assessed using the Rey auditory verbal learning test (RAVLT) and executive functioning using trail-making test B. Reduced striatal PDE10A was associated with increased amplitude of low-frequency fluctuations (ALFF) within the putamen and substantia nigra, respectively. Higher ALFF in the substantia nigra, in turn, was associated with lower episodic memory performance. The findings are in line with a role for PDE10A in striatal functioning, and suggest that reduced striatal PDE10A may contribute to cognitive symptoms in schizophrenia.

Bodén R, Sundström J, Lindström E, Lindström L (2009) Association between symptomatic remission and functional outcome in first-episode schizophrenia. Schizophr Res 107:232–237. https://doi.org/10.1016/j.schres.2008.10.004 CrossRefPubMed

Kapur S, Mamo D (2003) Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry 27:1081–1090. https://doi.org/10.1016/j.pnpbp.2003.09.004 CrossRefPubMed

Grauer SM, Pulito VL, Navarra RL et al (2009) Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia. J Pharmacol Exp Ther 331:574–590. https://doi.org/10.1124/jpet.109.155994 CrossRefPubMed

Reneerkens OAH, Rutten K, Bollen E et al (2013) Inhibition of phoshodiesterase type 2 or type 10 reverses object memory deficits induced by scopolamine or MK-801. Behav Brain Res 236:16–22. https://doi.org/10.1016/j.bbr.2012.08.019 CrossRefPubMed

Siuciak JA, Chapin DS, Harms JF et al (2006) Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis. Neuropharmacology 51:386–396. https://doi.org/10.1016/j.neuropharm.2006.04.013 CrossRefPubMed

Coskran TM, Morton D, Menniti FS et al (2006) Immunohistochemical localization of phosphodiesterase 10A in multiple Mammalian species. J Histochem Cytochem 54:1205–1213. https://doi.org/10.1369/jhc.6A6930.2006 CrossRefPubMed

Threlfell S, Sammut S, Menniti FS et al (2009) Inhibition of phosphodiesterase 10A increases the responsiveness of striatal projection neurons to cortical stimulation. J Pharmacol Exp Ther 328:785–795. https://doi.org/10.1124/jpet.108.146332 CrossRefPubMed

Gresack JE, Seymour PA, Schmidt CJ, Risbrough VB (2014) Inhibition of phosphodiesterase 10A has differential effects on dopamine D1 and D2 receptor modulation of sensorimotor gating. Psychopharmacol (Berl) 231:2189–2197. https://doi.org/10.1007/s00213-013-3371-7 CrossRef

DeMartinis N, Banerjee A, Kumar V et al (2012) Poster #212 results of a phase 2A proof-of-concept trial with a PDE10A inhibitor in the treatment of acute exacerbation of schizophrenia. Schizophr Res 136:S262. https://doi.org/10.1016/S0920-9964(12)70783-1 CrossRef

10.

Heckman PRA, Blokland A, Bollen EPP, Prickaerts J (2018) Phosphodiesterase inhibition and modulation of corticostriatal and hippocampal circuits: clinical overview and translational considerations. Neurosci Biobehav Rev 87:233–254. https://doi.org/10.1016/j.neubiorev.2018.02.007 CrossRefPubMed

11.

Bodén R, Persson J, Wall A et al (2017) Striatal phosphodiesterase 10A and medial prefrontal cortical thickness in patients with schizophrenia: a PET and MRI study. Transl Psychiatry 7:e1050. https://doi.org/10.1038/tp.2017.11 CrossRefPubMedPubMedCentral

12.

Fusar-Poli P, Meyer-Lindenberg A (2013) Striatal presynaptic dopamine in schizophrenia, part II: meta-analysis of [18F/11C]-DOPA PET studies. Schizophr Bull 39:33–42. https://doi.org/10.1093/schbul/sbr180 CrossRefPubMed

13.

Kegeles L, Frankle W, Gil R et al (2006) Schizophrenia is associated with increased synaptic dopamine in associative rather than limbic regions of the striatum: implications for mechanisms of action of antipsychotic drugs. J Nucl Med 47:139P–139P

14.

Kegeles LS, Abi-Dargham A, Frankle WG et al (2010) Increased synaptic dopamine function in associative regions of the striatum in schizophrenia. Arch Gen Psychiatry 67:231–239. https://doi.org/10.1001/archgenpsychiatry.2010.10 CrossRefPubMed

15.

Zang Y-F, He Y, Zhu C-Z et al (2007) Altered baseline brain activity in children with ADHD revealed by resting-state functional MRI. Brain Dev 29:83–91. https://doi.org/10.1016/j.braindev.2006.07.002 CrossRefPubMed

16.

Zuo X-N, Di Martino A, Kelly C et al (2010) The oscillating brain: complex and reliable. NeuroImage 49:1432–1445. https://doi.org/10.1016/j.neuroimage.2009.09.037 CrossRefPubMed

17.

He Z, Deng W, Li M et al (2013) Aberrant intrinsic brain activity and cognitive deficit in first-episode treatment-naive patients with schizophrenia. Psychol Med 43:769–780. https://doi.org/10.1017/S0033291712001638 CrossRefPubMed

18.

Huang X-Q, Lui S, Deng W et al (2010) Localization of cerebral functional deficits in treatment-naive, first-episode schizophrenia using resting-state fMRI. NeuroImage 49:2901–2906. https://doi.org/10.1016/j.neuroimage.2009.11.072 CrossRefPubMed

19.

Li Z, Lei W, Deng W et al (2017) Aberrant spontaneous neural activity and correlation with evoked-brain potentials in first-episode, treatment-naïve patients with deficit and non-deficit schizophrenia. Psychiatry Res Neuroimaging 261:9–19. https://doi.org/10.1016/j.pscychresns.2017.01.001 CrossRefPubMed

20.

Meda SA, Wang Z, Ivleva EI et al (2015) Frequency-specific neural signatures of spontaneous low-frequency resting state fluctuations in psychosis: evidence from bipolar-schizophrenia network on intermediate phenotypes (B-SNIP) consortium. Schizophr Bull 41:1336–1348. https://doi.org/10.1093/schbul/sbv064 CrossRefPubMedPubMedCentral

21.

Dong D, Wang Y, Chang X et al (2018) Dysfunction of large-scale brain networks in schizophrenia: a meta-analysis of resting-state functional connectivity. Schizophr Bull 44:168–181. https://doi.org/10.1093/schbul/sbx034 CrossRefPubMed

22.

McCutcheon RA, Nour MM, Dahoun T et al (2018) Mesolimbic dopamine function is related to salience network connectivity: an integrative positron emission tomography and magnetic resonance study. Biol Psychiatry. https://doi.org/10.1016/j.biopsych.2018.09.010 CrossRefPubMed

23.

Umbricht D, Krljes S (2005) Mismatch negativity in schizophrenia: a meta-analysis. Schizophr Res 76:1–23. https://doi.org/10.1016/j.schres.2004.12.002 CrossRefPubMed

24.

Gaebler AJ, Mathiak K, Koten JW et al (2015) Auditory mismatch impairments are characterized by core neural dysfunctions in schizophrenia. Brain 138:1410–1423. https://doi.org/10.1093/brain/awv049 CrossRefPubMedPubMedCentral

25.

Ardila A, Bernal B, Rosselli M (2018) Executive functions brain system: an activation likelihood estimation meta-analytic study. Arch Clin Neuropsychol 33:379–405. https://doi.org/10.1093/arclin/acx066 CrossRefPubMed

26.

Arsalidou M, Duerden EG, Taylor MJ (2013) The centre of the brain: topographical model of motor, cognitive, affective, and somatosensory functions of the basal ganglia. Hum Brain Mapp 34:3031–3054. https://doi.org/10.1002/hbm.22124 CrossRefPubMed

27.

Cervenka S, Bäckman L, Cselényi Z et al (2008) Associations between dopamine D2-receptor binding and cognitive performance indicate functional compartmentalization of the human striatum. NeuroImage 40:1287–1295. https://doi.org/10.1016/j.neuroimage.2007.12.063 CrossRefPubMed

28.

Veselinović T, Vernaleken I, Janouschek H et al (2018) The role of striatal dopamine D2/3 receptors in cognitive performance in drug-free patients with schizophrenia. Psychopharmacol (Berl) 235:2221–2232. https://doi.org/10.1007/s00213-018-4916-6 CrossRef

29.

Lawyer G, Nyman H, Agartz I, Arnborg S, Jönsson EG, Sedvall GC, Hall H (2006) Morphological correlates to cognitive dysfunction in schizophrenia as studied with Bayesian regression. BMC Psychiatry 6:31. https://doi.org/10.1186/1471-244X-6-31 CrossRefPubMedCentral

30.

Nyberg L, Karalija N, Salami A, Andersson M, Wåhlin A (2016) Dopamine D2 receptor availability is linked to hippocampal-caudate functional connectivity and episodic memory. PNAS 113:7918–7923. https://doi.org/10.1073/pnas.1606309113 CrossRefPubMed

31.

Schott BH, Seidenbecher CI, Fenker DB et al (2006) The dopaminergic midbrain participates in human episodic memory formation: evidence from genetic imaging. J Neurosci 26:1407–1417. https://doi.org/10.1523/JNEUROSCI.3463-05.2006 CrossRefPubMedPubMedCentral

32.

Scimeca JM, Badre D (2012) Striatal contributions to declarative memory retrieval. Neuron 75:380–392. https://doi.org/10.1016/j.neuron.2012.07.014 CrossRefPubMedPubMedCentral

33.

Tomimatsu Y, Cash D, Suzuki M et al (2016) TAK-063, a phosphodiesterase 10A inhibitor, modulates neuronal activity in various brain regions in phMRI and EEG studies with and without ketamine challenge. Neuroscience 339:180–190. https://doi.org/10.1016/j.neuroscience.2016.10.006 CrossRefPubMed

34.

Badcock JC, Dragovic M, Dawson L, Jones R (2011) Normative data for Rey’s auditory verbal learning test in individuals with schizophrenia. Arch Clin Neuropsychol 26:205–213. https://doi.org/10.1093/arclin/acr005 CrossRefPubMed

35.

Leucht S, Samara M, Heres S et al (2015) Dose equivalents for second-generation antipsychotic drugs: the classical mean dose method. Schizophr Bull 41:1397–1402. https://doi.org/10.1093/schbul/sbv037 CrossRefPubMedPubMedCentral

36.

Kehler J, Kilburn JP, Estrada S et al (2014) Discovery and development of 11C-Lu AE92686 as a radioligand for PET imaging of phosphodiesterase10A in the brain. J Nucl Med 55:1513–1518. https://doi.org/10.2967/jnumed.114.140178 CrossRefPubMed

37.

Chao-Gan Y, Yu-Feng Z (2010) DPARSF: a MATLAB toolbox for “Pipeline” data analysis of resting-state fMRI. Front Syst Neurosci. https://doi.org/10.3389/fnsys.2010.00013 CrossRefPubMedPubMedCentral

38.

Friston KJ, Williams S, Howard R et al (1996) Movement-related effects in fMRI time-series. Magn Reson Med 35:346–355. https://doi.org/10.1002/mrm.1910350312 CrossRefPubMed

39.

Murphy JR, Rawdon C, Kelleher I et al (2013) Reduced duration mismatch negativity in adolescents with psychotic symptoms: further evidence for mismatch negativity as a possible biomarker for vulnerability to psychosis. BMC Psychiatry 13:45. https://doi.org/10.1186/1471-244X-13-45 CrossRefPubMedPubMedCentral

40.

Reitan RM (1958) Validity of the trail making test as an indicator of organic brain damage. Percept Mot Skills 8:271–276. https://doi.org/10.2466/pms.1958.8.3.271 CrossRef

41.

Kortte KB, Horner MD, Windham WK (2002) The trail making test, part b: cognitive flexibility or ability to maintain set? Appl Neuropsychol 9:106–109. https://doi.org/10.1207/S15324826AN0902_5 CrossRefPubMed

42.

Tziortzi AC, Searle GE, Tzimopoulou S et al (2011) Imaging dopamine receptors in humans with [11C]-(+)-PHNO: dissection of D3 signal and anatomy. NeuroImage 54:264–277. https://doi.org/10.1016/j.neuroimage.2010.06.044 CrossRefPubMed

43.

Polito M, Guiot E, Gangarossa G et al (2015) Selective effects of PDE10A inhibitors on striatopallidal neurons require phosphatase inhibition by DARPP-32. eNeuro. https://doi.org/10.1523/ENEURO.0060-15.2015 CrossRefPubMedPubMedCentral

44.

Surmeier DJ, Song W-J, Yan Z (1996) Coordinated expression of dopamine receptors in neostriatal medium spiny neurons. J Neurosci 16:6579–6591. https://doi.org/10.1523/JNEUROSCI.16-20-06579.1996 CrossRefPubMedPubMedCentral

45.

Humphries MD, Lepora N, Wood R, Gurney K (2009) Capturing dopaminergic modulation and bimodal membrane behaviour of striatal medium spiny neurons in accurate, reduced models. Front Comput Neurosci. https://doi.org/10.3389/neuro.10.026.2009 CrossRefPubMedPubMedCentral

46.

Moyer JT, Wolf JA, Finkel LH (2007) Effects of dopaminergic modulation on the integrative properties of the ventral striatal medium spiny neuron. J Neurophysiol 98:3731–3748. https://doi.org/10.1152/jn.00335.2007 CrossRefPubMed

47.

Liu C, Xue Z, Palaniyappan L et al (2016) Abnormally increased and incoherent resting-state activity is shared between patients with schizophrenia and their unaffected siblings. Schizophr Res 171:158–165. https://doi.org/10.1016/j.schres.2016.01.022 CrossRefPubMed

48.

Piccart E, De Backer J-F, Gall D et al (2014) Genetic deletion of PDE10A selectively impairs incentive salience attribution and decreases medium spiny neuron excitability. Behav Brain Res 268:48–54. https://doi.org/10.1016/j.bbr.2014.03.016 CrossRefPubMed

49.

Beaumont V, Zhong S, Lin H et al (2016) Phosphodiesterase 10A inhibition improves cortico-basal ganglia function in Huntington’s disease models. Neuron 92:1220–1237. https://doi.org/10.1016/j.neuron.2016.10.064 CrossRefPubMed

50.

Ooms M, Celen S, De Hoogt R et al (2017) Striatal phosphodiesterase 10A availability is altered secondary to chronic changes in dopamine neurotransmission. Ejnmmi Radiopharm Chem. https://doi.org/10.1186/s41181-016-0005-5 CrossRefPubMed

51.

Dlaboga D, Hajjhussein H, O’Donnell JM (2008) Chronic haloperidol and clozapine produce different patterns of effects on phosphodiesterase-1B, -4B, and -10A expression in rat striatum. Neuropharmacology 54:745–754. https://doi.org/10.1016/j.neuropharm.2007.12.002 CrossRefPubMed

52.

Natesan S, Ashworth S, Nielsen J et al (2014) Effect of chronic antipsychotic treatment on striatal phosphodiesterase 10A levels: a [¹¹C]MP-10 PET rodent imaging study with ex vivo confirmation. Transl Psychiatry 4:e376. https://doi.org/10.1038/tp.2014.17 CrossRefPubMedPubMedCentral

53.

Dreyer JK, Herrick KF, Berg RW, Hounsgaard JD (2010) Influence of phasic and tonic dopamine release on receptor activation. J Neurosci 30:14273–14283. https://doi.org/10.1523/JNEUROSCI CrossRefPubMedPubMedCentral

54.

Cosottini M, Frosini D, Pesaresi I, Costagli M, Biagi L, Ceravolo R, Bonuccelli U, Tosetti M (2014) MR imaging of the substantia Nigra at 7 T enables diagnosis of Parkinson disease. Radiology 271:818–838. https://doi.org/10.1148/radiol.14131448 CrossRef

55.

Velíšková J, Moshé SL (2006) Update on the role of substantia Nigra pars reticulata in the regulation of seizures. Epilepsy Curr 6:83–87. https://doi.org/10.1111/j.1535-7511.2006.00106.x CrossRefPubMedPubMedCentral

56.

Tepper JM, Lee CR (2007) GABAergic control of substantia nigra dopaminergic neurons. Prog Brain Res 160:189–208. https://doi.org/10.1016/S0079-6123(06)60011-3 CrossRefPubMed

Title: Phosphodiesterase 10A levels are related to striatal function in schizophrenia: a combined positron emission tomography and functional magnetic resonance imaging study
Authors: Jonas Persson
K. Szalisznyó
G. Antoni
A. Wall
D. Fällmar
H. Zora
R. Bodén
Publication date: 01-06-2020
Publisher: Springer Berlin Heidelberg
Keywords: Schizophrenia
Magnetic Resonance Imaging
Magnetic Resonance Imaging
Positron Emission Tomography
Published in: European Archives of Psychiatry and Clinical Neuroscience / Issue 4/2020
Print ISSN: 0940-1334
Electronic ISSN: 1433-8491
DOI: https://doi.org/10.1007/s00406-019-01021-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Phosphodiesterase 10A levels are related to striatal function in schizophrenia: a combined positron emission tomography and functional magnetic resonance imaging study

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2020

Reduced Annexin A3 in schizophrenia

Binding varicella zoster virus: an underestimated facet of insulin-degrading enzyme´s implication for Alzheimer´s disease pathology?

Polygenic analysis suggests the involvement of calcium signaling in executive function in schizophrenia patients

Three plasma metabolites in elderly patients differentiate mild cognitive impairment and Alzheimer’s disease: a pilot study

Cannabis use and psychosis: a review of reviews

Association between altered hippocampal oligodendrocyte number and neuronal circuit structures in schizophrenia: a postmortem analysis